PROTAC c-Met degrader-6

PROTAC c-Met degrader-6 是一种强效且口服有效的 c-Met PROTAC 降解剂,可显著诱导 c-Met 蛋白降解,在 EBC-1 和 Hs746T 细胞中的 DC50 值分别为 0.52 nM 和 0.45 nM,几乎完全消除肿瘤细胞的迁移和侵袭能力,显著诱导细胞凋亡 (apoptosis),并将细胞周期阻断于 G0/G1 期,可用于非小细胞肺癌和胃癌等多种癌症的研究(粉色:c-Met 靶蛋白配体;蓝色:Cereblon 配体 (MS-B42308);黑色:连接子 (MS-P93294))。
PROTAC c-Met degrader-6
产品编号: MS-L49934 分子式: C41H35N9O6 分子量: 749.77
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PROTAC c-Met degrader-6 是一种强效且口服有效的 c-Met PROTAC 降解剂,可显著诱导 c-Met 蛋白降解,在 EBC-1 和 Hs746T 细胞中的 DC50 值分别为 0.52 nM 和 0.45 nM,几乎完全消除肿瘤细胞的迁移和侵袭能力,显著诱导细胞凋亡 (apoptosis),并将细胞周期阻断于 G0/G1 期,可用于非小细胞肺癌和胃癌等多种癌症的研究(粉色:c-Met 靶蛋白配体;蓝色:Cereblon 配体 (MS-B42308);黑色:连接子 (MS-P93294))。

生物实验数据

生物活性 PROTAC c-Met degrader-6 is a potent and orally active c-Met PROTAC degrader that significantly induces c-Met protein degradation with DC50 values of 0.52 nM and 0.45 nM in EBC-1 and Hs746T cells, respectively, almost completely abolishes tumor cell migration and invasion, markedly induces apoptosis, and blocks the cell cycle at G0/G1 phase, and can be used for research on multiple cancers such as non-small cell lung cancer and gastric cancer (pink: c-Met target protein ligand; blue: Cereblon ligand (MS-B42308); black: linker (MS-P93294)).
IC50 & Target

c-Met

 

体外研究
(In Vitro)

PROTAC c-Met degrader-6 (Compound G4) (72 h) 具有抗增殖功效,在 EBC-1、Hs746T 和 MHCC97H 细胞中的 IC50 值分别为 3.55、3.01 和 7.48 nM。
PROTAC c-Met degrader-6 (1-10 nM,48 h) 在 EBC-1 和 Hs746T 细胞中通过泛素-蛋白酶体途径显著降解 c-Met。
PROTAC c-Met degrader-6 (5-10 nM,24-48 h) 在诱导细胞凋亡、G1 期细胞周期阻滞以及抑制细胞迁移和侵袭方面表现出强大的作用。
PROTAC c-Met degrader-6 (100-1000 nM, 48 h-3 days) 对携带 c-MetD1228N 和 c-MetY1230H 突变体的 EBC-1 和 Hs746T 细胞具有优异的抗增殖作用。
PROTAC c-Met degrader-6 在人肝微粒体和小鼠肝微粒体中具有良好的代谢稳定性。

Apoptosis Analysis

Cell Line: EBC-1 and Hs746T cells
Concentration: 10 nM
Incubation Time: 48 h
Result: Produced the apoptosis rates of 21.8% in EBC-1 and observed similar results in Hs746T.

Cell Cycle Analysis

Cell Line: EBC-1 and Hs746T cells
Concentration: 10 nM
Incubation Time: 48 h
Result: Induced cell cycle arrest at the G0/G1 phase.

Cell Migration Assay

Cell Line: EBC-1 and Hs746T cells
Concentration: 5 nM
Incubation Time: 24 h
Result: Significantly inhibited the migratory capacity.

Cell Invasion Assay

Cell Line: EBC-1 and Hs746T cells
Concentration: 5 nM
Incubation Time: 24 h
Result: Significantly inhibited the invasive capacity.

Western Blot Analysis

Cell Line: EBC-1 and Hs746T cells
Concentration: 1 and 10 nM
Incubation Time: 48 h
Result: Significantly inhibited the levels of c-Met phosphorylation (p-c-Met) and STAT3 phosphorylation (p-STAT3) at 1nM
Completely blocked the c-Met degradation effect pretreatment with MLN4924 (E1 ubiquitin-activating enzyme inhibitor) (MS-C57164) and MG132 (proteasome inhibitor) (MS-L06849).

Western Blot Analysis

Cell Line: EBC-1 and Hs746T cells harboring a D1228N mutation
Concentration: 100 and 1000 nM
Incubation Time: 48 h
Result: Inhibited the p-c-Met level, and complete c-Met degradation and p-c-Met inhibition.
体内研究
(In Vivo)

PROTAC c-Met degrader-6 (Compound G4) (5-10 mg/kg, p.o., 每日一次共 18 天) 在 EBC-1 异种移植小鼠模型中能显著抑制肿瘤生长。

Animal Model: EBC-1 xenografts model established in NOD/SCID mice (6 week-old)
Dosage: 5 and 10 mg/kg
Administration: Orally administration (p.o.), once daily for 18 days
Result: Significantly inhibited EBC-1 tumor growth, with tumor growth inhibition (TGI %) values of 84.12% at 5 mg/kg and 99.28% at 10 mg/kg after 10 days
Demonstrated complete tumor inhibition during the extended period (by day 18) at 10 mg/kg.
Exhibited a notable reduction in the percentage of Ki67-and CD31-positive tumor cells and an Increased percentage of cleaved caspase 3-positive tumor cells.
Exhibited more potent effects on reducing the level of p-c-Met and p-STAT3.
No obvious body weight loss and no other obvious toxic signs.

化学信息

分子量 749.77
分子式 C41H35N9O6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础